Zometa chemical name: zoledronic acid is used to strengthen bones and lower the risk of breaking a bone and other bone complications in women diagnosed with metastatic breast cancer that has spread to the bones. Earlier research suggested that Zometa also might help stop breast cancer from spreading to the bones by making it harder for breast cancer cells to grow in bones and might help reduce the risk of the cancer coming back recurrence in women diagnosed with early-stage breast cancer. Results from three studies all suggest that Zometa can help reduce the risk of cancer recurrence when it's included from the start in treating hormone-receptor-positive early-stage breast cancer in postmenopausal and older premenopausal women. More than 1, premenopausal women diagnosed with stage I or II hormone-receptor-positive breast cancer participated in this study.
Where Are We With Bone-Targeted Agents in Breast Cancer?
Bisphosphonates, a class of drugs well-known to prevent and treat osteoporosis , are also used in cancer treatment. Generally, they are used for cancer-related bone pain and hypercalcemia. In breast cancer specifically, bisphosphonates are primarily used to reduce the risk of fracture and osteoporosis in postmenopausal women. But research suggests that these drugs may offer the additional benefit of preventing recurrence of metastatic breast cancer in bone. There is even evidence that bisphosphonates may improve survival times in premenopausal and postmenopausal women with early-stage breast cancer.
Post a Comment. Can Zometa zoledronic acid prevent recurrence in women with early-stage breast cancer? Today we'll share the latest news and research.
Metrics details. Zoledronic acid ZA is an imidazole-containing bisphosphonate that has been extensively studied as an osteoclast inhibitor. ZA decreases bone turnover and has been effective in limiting osteolysis in metastatic cancers, including breast cancer. Recent clinical trials that demonstrated enhancement of disease-free survival by bisphosphonates have prompted interest in bisphosphonates as anti-cancer agents.